Serving leading biopharmaceutical companies globally:

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

I - Biologic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Company Disclosures: US Patents for i

These patents were extracted from company disclosures

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Bayer Healthcare Pharms	BETASERON	interferon beta-1b	VIAL; SUBCUTANEOUS	103471	001	1993-07-23	Start Trial	Cetus Corporation (Emeryville, CA)	2039-03-29	RX	Orphan	company
Bayer Healthcare Pharms	BETASERON	interferon beta-1b	VIAL; SUBCUTANEOUS	103471	001	1993-07-23	Start Trial	Cetus Corporation (Emeryville, CA)	2004-03-28	RX	Orphan	company
Bayer Healthcare Pharms	BETASERON	interferon beta-1b	VIAL; SUBCUTANEOUS	103471	001	1993-07-23	Start Trial	Cetus Corporation (Emeryville, CA)	2003-05-13	RX	Orphan	company
Bayer Healthcare Pharms	BETASERON	interferon beta-1b	VIAL; SUBCUTANEOUS	103471	001	1993-07-23	Start Trial	Cetus Corporation (Emeryville, CA)	2005-04-12	RX	Orphan	company
Bayer Healthcare Pharms	BETASERON	interferon beta-1b	VIAL; SUBCUTANEOUS	103471	001	1993-07-23	Start Trial	Cetus Corporation (Emeryville, CA)	2002-10-19	RX	Orphan	company
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

Patent Text Search: US Patents for i

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Vidara Therapeutics Research Ltd	ACTIMMUNE	interferon gamma-1b	VIAL; SINGLE-USE	103836	001	1999-02-25	Start Trial		2033-02-06	RX		search
Vidara Therapeutics Research Ltd	ACTIMMUNE	interferon gamma-1b	VIAL; SINGLE-USE	103836	001	1999-02-25	Start Trial	First Circle Medical, Inc. (Minneapolis, MN)	2039-02-26	RX		search
Vidara Therapeutics Research Ltd	ACTIMMUNE	interferon gamma-1b	VIAL; SINGLE-USE	103836	001	1999-02-25	Start Trial	First Circle Medical, Inc. (Minneapolis, MN)	2039-02-26	RX		search
Vidara Therapeutics Research Ltd	ACTIMMUNE	interferon gamma-1b	VIAL; SINGLE-USE	103836	001	1999-02-25	Start Trial		2019-09-09	RX		search
Vidara Therapeutics Research Ltd	ACTIMMUNE	interferon gamma-1b	VIAL; SINGLE-USE	103836	001	1999-02-25	Start Trial	First Circle Medical, Inc. (Minneapolis, MN)	2039-02-26	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon

McKesson

Medtronic

Boehringer Ingelheim

McKinsey

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.